NARB affirms NAD in the Tru Niagen matter

The National Advertising Review Board (NARB), the appellate body of BBB National Programs, upheld the National Advertising Division's (NAD) March 16, 2026 recommendations that Niagen Bioscience discontinue "clinically proven" claims and several health-benefit claims for its Tru Niagen dietary supplement ^[1][2]. The panel found NAD "applied the proper legal standard" and followed Federal Trade Commission precedent ^[2].

The case began with a challenge from competitor Reus Research LLC, which makes its own NAD+ products ^[1]. Reus targeted Tru Niagen advertising that it said conveyed unsupported messages about raising NAD+ levels, organ-specific benefits, vitality and anti-aging effects, cellular-level benefits, and effects consumers could actually feel, along with the company's use of testimonials and influencers ^[1].

What NAD found

NAD reviewed the express claim that Tru Niagen is "clinically proven to significantly increase NAD+ levels, and help maintain them with daily use," plus a separate claim that NAD+ levels rise within hours and show significant increases within two weeks ^[1]. The record did include studies showing that nicotinamide riboside, the product's active ingredient, can raise NAD+ under certain conditions ^[1]. But NAD concluded that differences in study design, populations, duration, endpoints and conditions of use limited how far that evidence stretched, and recommended the company drop the unqualified "clinically proven" claim and the timing claim as presented ^[1].

On health benefits, NAD drew a line between evidence showing a biomarker or mechanism changed and evidence showing a functional health outcome in consumers ^[1]. It said claims framed at the cellular level — for example, "supports cellular energy that your heart cells need" — can, in context, reasonably convey that consumers will notice a benefit ^[1]. Where cardiovascular, cognitive, immune, metabolic, exercise, anti-aging or cellular-repair benefits were not substantiated, NAD recommended the claims be modified or discontinued ^[1]. It also recommended dropping certain consumer testimonials and told the company to ensure influencer material connections are disclosed clearly in both audio and visual portions of content, consistent with the FTC Endorsement Guides ^[1]. Niagen separately agreed during the case to permanently stop reproductive health, sleep improvement and "Made in the USA" claims, which NAD did not review on the merits ^[1].

The DSHEA argument, rejected

Niagen's central appeal argument was that the disputed statements were structure/function claims permitted under the Dietary Supplement Health and Education Act of 1994, which the FDA administers ^[2]. NAD disagreed, citing FTC guidance that "the Commission regards DSHEA status as a regulatory (FDA) matter, not as a consideration relevant to an assessment of whether a health claim is misleading or properly supported" ^[2]. The bottom line, per the coverage: substantiation depends on the message conveyed to consumers, not where a claim sits in the regulatory framework ^[2].

Niagen also argued NAD critiqued studies in isolation rather than weighing the totality of the evidence, and that the outcome creates "an unworkable standard moving forward" ^[2]. Carlos Lopez, the company's senior vice president and general counsel, said Niagen is "deeply disappointed by the NARB panel's decision, which we believe applies an overly restrictive standard that is inconsistent with long-standing dietary supplement law, scientific practice and established advertising precedent" ^[2]. He emphasized the dispute is about interpreting advertising claims, not product safety or quality ^[2].

Reus countered that the classification of the claims as structure/function statements is irrelevant, and that Niagen markets to older consumers who may be especially vulnerable to unsubstantiated claims ^[2]. Roman Miroedov, product development lead at Cata-Kor, said "NARB's decision confirms that the message conveyed to consumers is what matters, not the advertiser's regulatory framing" ^[2].

Why it matters for patients

This case is about an NAD+ supplement, not a GLP-1 medication, and the sources do not address GLP-1 products at all. But the standard it applies covers dietary supplement advertising generally — including the growing category of pills and powders sold alongside or instead of prescription drugs.

The practical takeaway from the decision is that a "clinically proven" label on a supplement is a strong claim with a high evidentiary bar. Asa Waldstein of Apex Compliance said a reasonable consumer could take it to mean the finished product, or a very comparable form, dose, strength and use pattern, was studied and delivered the stated result, and that a double-blind, placebo-controlled human trial is "often the gold standard" for that ^[2]. He added that if the evidence is narrower than the claim, the claim usually needs to be narrowed too ^[2].

It also matters that NAD separated mechanism from outcome: showing a supplement shifts a lab marker is not the same as showing people feel or function better ^[1].

What happens next

NAD issued its recommendations on March 16, 2026, and Niagen appealed ^[1]. The NARB panel's affirmation was reported May 22, 2026 ^[2]. NAD and NARB are industry self-regulatory bodies, and the panel thanked both companies "for participating in industry self-regulation in the interest of promoting truth in advertising" ^[2]. Whether and how Niagen will change its advertising following the appeal is not stated in the sources.